
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
August 9, 2022

CLEARPOINT NEURO, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34822
(Commission
File Number)

58-2394628
(I.R.S. Employer
Identification Number)

120 S. Sierra Ave., Suite 100
Solana Beach, CA 92075
(Address of principal executive offices, zip code)

(888) 287-9109
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CLPT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On August 9, 2022, ClearPoint Neuro, Inc. (the “Company”) issued a press release announcing its financial performance for the second fiscal quarter ended June 30, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On August 9, 2022, the Company posted an updated investor presentation to its website at <http://ir.stockpr.com/clearpointneuro/investor-presentations>. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1	Press Release dated August 9, 2022
Exhibit 99.2	Investor Presentation dated August 9, 2022
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 9, 2022

CLEARPOINT NEURO, INC.

By: /s/ Danilo D'Alessandro
Danilo D'Alessandro
Chief Financial Officer



ClearPoint Neuro Reports Second Quarter 2022 Results Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast

SOLANA BEACH, CA, August 9, 2022 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2022.

Second Quarter Highlights

- Reported record quarterly revenue of \$5.2 million, a 52% year-over-year increase;
- Partner PTC Therapeutics received a positive opinion for its gene therapy treatment Upstaza™ from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Upstaza, which was granted full marketing authorization by the European Commission in July 2022, will be administered with the Company’s SmartFlow® Neuro Cannula;
- Increased biologics and drug delivery revenue to \$2.4 million, a 73% year-over-year increase;
- Added multiple new biologics and drug delivery partners in the quarter to bring the total to more than 45;
- Installed four additional systems in the quarter bringing the total to 8 new installations year-to-date;
- Achieved Medical Device Single Audit Program (MDSAP) certification paving the way for additional international regulatory submissions in support of pharmaceutical partners; and
- Cash and short-term investments totaled \$45.1 million as of June 30, 2022.

Business Outlook

- The Company reaffirms its full year 2022 revenue outlook of between \$21.0 and \$22.0 million.

“The ClearPoint Neuro Team has continued to execute against our four-pillar growth strategy in the second quarter,” commented Joe Burnett, President and CEO. “We achieved another record quarter for revenue and over 50% growth despite an elevated case cancellation rate and supply chain disruptions. Our biologics and drug delivery business led the way and became our largest segment with product and service revenue growing at more than 70%. The team also added multiple new pharma and academic partners bringing our total to more than 45 and keeping pace at approximately one new partner each month. Our ClearPoint Navigation system was installed at four additional centers bringing the total new centers to eight in 2022 across the U.S. and Europe. Our product development team continues to execute on our pipeline and has additional products being reviewed by global regulatory bodies.

Particularly of note, the European Commission granted marketing authorization for Upstaza to our partner PTC Therapeutics. Upstaza is the first gene therapy approved anywhere in the world to be dosed by direct infusion into the brain. Consistent with our long term strategy, the Summary of Product Characteristics for Upstaza specifically includes the ClearPoint SmartFlow Neuro Cannula as the device used for minimally invasive infusion of the gene therapy. We believe the approval of Upstaza, delivered with ClearPoint’s cannula, demonstrates the viability and potential of our drug delivery partnerships.

At present, we are reaffirming our prior guidance of revenue between \$21.0 and \$22.0 million for the year.”

Financial Results – Quarter Ended June 30, 2022

Total revenue was \$5.2 million for the three months ended June 30, 2022, and \$3.4 million for the three months ended June 30, 2021, which represents an increase of \$1.8 million, or 52%.

Functional neurosurgery navigation and therapy revenue, increased 17% to \$2.2 million for the three months ended June 30, 2022, from \$1.9 million for the same period in 2021. The growth was driven by higher service revenue.

Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored clinical trials utilizing our products, increased 73% to \$2.4 million for the three months ended June 30, 2022, from \$1.4 million for the same period in 2021. This increase is attributable to a \$0.8 million increase in product revenue and \$0.2 million increase in service revenue.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, increased 282% to \$0.6 million for the three months ended June 30, 2022, from \$0.2 million for the same period in 2021 due to an increase in the sale of ClearPoint systems.

Gross margin for the three months ended June 30, 2022, was 63%, as compared to a gross margin of 67%, for the three months ended June 30, 2021. The decrease in gross margin was due primarily to an increase in overhead expenses, excess and obsolete reserves, and product mix.

Operating expenses for the second quarter of 2022 were \$7.5 million, compared to \$5.7 million for the second quarter of 2021. The increase was mainly driven by the increase in headcount across the organization, product development expenses and share based compensation.

At June 30, 2022, the Company had cash and cash equivalents and short-term investments totaling \$45.1 million as compared to \$54.1 million at December 31, 2021, with the decrease resulting primarily from the use of cash in operating activities of \$9.3 million.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2022 second quarter on Tuesday, August 9, 2022 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: <https://event.choruscall.com/mediaframe/webcast.html?webcastid=LzXg7k1V>. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 437-3179, or at (404) 267-0369 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until September 9, 2022, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at <https://ir.clearpointneuro.com/>.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with more than 45 pharmaceutical and biotech companies, academic institutions, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the

Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2022, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2022, which the Company intends to file with the Securities and Exchange Commission on or before August 15, 2022.

Contact:

Danilo D'Alessandro, Chief Financial Officer

(949) 900-6833

info@clearpointneuro.com

Caroline Corner, Investor Relations

ir@clearpointneuro.com

CLEARPOINT NEURO, INC.
Consolidated Statements of Operations
(Unaudited)
(Dollars in thousands, except for per share data)

	For The Three Months Ended June 30,	
	2022	2021
Revenue:		
Product revenue	\$ 3,457	\$ 2,363
Service and other revenue	1,743	1,050
Total revenue	5,200	3,413
Cost of revenue	1,943	1,139
Gross profit	3,257	2,274
Research and development costs	2,284	2,109
Sales and marketing expenses	2,187	1,590
General and administrative expenses	2,990	1,982
Operating loss	(4,204)	(3,407)
Other expense:		
Other expense, net	(8)	(96)
Interest expense, net	(91)	(240)
Net loss	\$ (4,303)	\$ (3,743)
Net loss per share attributable to common stockholders:		
Basic and diluted	\$ (0.18)	\$ (0.17)
Weighted average shares used in computing net loss per share:		
Basic and diluted	23,985,577	21,523,393

	For The Six Months Ended June 30,	
	2022	2021
Revenue:		
Product revenue	\$ 6,620	\$ 5,525
Service and other revenue	3,611	1,918
Total revenue	10,231	7,443
Cost of revenue	3,728	2,555
Gross profit	6,503	4,888
Research and development costs	4,817	3,673
Sales and marketing expenses	4,032	3,165
General and administrative expenses	5,722	3,638
Operating loss	(8,068)	(5,588)
Other expense:		
Other income (expense), net	3	(122)
Interest expense, net	(197)	(571)
Net loss	\$ (8,262)	\$ (6,281)
Net loss per share attributable to common stockholders:		
Basic and diluted	\$ (0.35)	\$ (0.31)
Weighted average shares used in computing net loss per share:		
Basic and diluted	23,834,847	20,195,488

CLEARPOINT NEURO, INC.
Consolidated Balance Sheets
(Dollars in thousands, except for per share data)

	June 30, 2022 (Unaudited)	December 31, 2021
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 23,524	\$ 54,109
Short-term investments	21,613	—
Accounts receivable, net	3,348	2,337
Inventory, net	6,639	4,938
Prepaid expenses and other current assets	1,517	508
Total current assets	56,641	61,892
Property and equipment, net	689	539
Operating lease rights of use	1,992	2,241
Software license inventory	504	519
Licensing rights	320	265
Other assets	94	125
Total assets	\$ 60,240	\$ 65,581
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 1,592	\$ 427
Accrued compensation	1,814	2,604
Other accrued liabilities	870	537
Operating lease liabilities, current portion	532	507
Deferred product and service revenue, current portion	675	678
Total current liabilities	5,483	4,753
Operating lease liabilities, net of current portion	1,671	1,939
Deferred product and service revenue, net of current portion	401	264
2020 senior secured convertible notes payable, net	9,865	9,838
Total liabilities	17,420	16,794
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$0.01 par value; 25,000,000 shares authorized; none issued and outstanding at June 30, 2022 and December 31, 2021	—	—
Common stock, \$0.01 par value; 200,000,000 shares authorized; 24,480,600 shares issued and outstanding at June 30, 2022; and 23,665,991 issued and outstanding at December 31, 2021	245	237
Additional paid-in capital	184,769	182,482
Accumulated deficit	(142,194)	(133,932)
Total stockholders' equity	42,820	48,787
Total liabilities and stockholders' equity	\$ 60,240	\$ 65,581

CLEARPOINT NEURO, INC.
Consolidated Statements of Cash Flows
(Unaudited)
(Dollars in thousands)

	For The Six Months Ended June 30,	
	2022	2021
Cash flows from operating activities:		
Net loss	\$ (8,262)	\$ (6,281)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Allowance for doubtful accounts	(10)	92
Depreciation and amortization	187	62
Share-based compensation	1,779	567
Payment-in-kind interest	—	189
Amortization of debt issuance costs and original issue discounts	27	54
Amortization of lease rights of use, net of accretion in lease liabilities	267	267
Accretion of discounts on short-term investments	(23)	—
Increase (decrease) in cash resulting from changes in:		
Accounts receivable	(1,001)	(617)
Inventory, net	(1,786)	(304)
Prepaid expenses and other current assets	(1,010)	(760)
Other assets	30	(93)
Accounts payable and accrued expenses	679	1,312
Lease liabilities	(261)	(195)
Deferred revenue	134	(142)
Net cash flows from operating activities	<u>(9,250)</u>	<u>(5,849)</u>
Cash flows from investing activities:		
Purchases of property and equipment	(145)	(5)
Acquisition of licensing rights	(116)	—
Purchase of short-term investments	(21,590)	—
Net cash flows from investing activities	<u>(21,851)</u>	<u>(5)</u>
Cash flows from financing activities:		
Proceeds from public offering of common stock, net of offering costs	—	46,785
Proceeds from stock option and warrant exercises	256	494
Proceeds from issuance of common stock under employee stock purchase plan	260	—
Net cash flows from financing activities	<u>516</u>	<u>47,279</u>
Net change in cash and cash equivalents	(30,585)	41,425
Cash and cash equivalents, beginning of period	54,109	20,099
Cash and cash equivalents, end of period	<u>\$ 23,524</u>	<u>\$ 61,524</u>
SUPPLEMENTAL CASH FLOW INFORMATION		
Cash paid for:		
Income taxes	\$ —	\$ —
Interest	<u>\$ 207</u>	<u>\$ 353</u>



CLEARPOINT®
NEURO

WHEN YOUR PATH IS UNCLEAR,
WE POINT THE WAY.™


Nasdaq: CLPT

August 2022



Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2022, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2022, which the Company intends to file with the Securities and Exchange Commission on or before August 15, 2022.

ClearPoint Neuro: Two Opportunities, One Platform



- ←→
- A Common Installed Base Platform and Clinical Specialist Support team
 - 35 Active Indications totaling more than 1 million patients diagnosed annually
 - A \$12B+ Potential Total Addressable Market

1 A Biologics & Drug Delivery Enabling Company with;

- A unique portfolio of Navigation Tools, Infusion Cannulas, Pre-Clinical and Clinical Services
- More than 45 active pharma/biotech, academic and contract research organization partners

2 A Neuro Navigation and Device Company with;

- A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation
- An expanding global installed base of more than 60 centers

Our Company

ClearPoint Neuro: A Proven Platform

Key Products: **FDA CE** Marked Platforms

HEADQUARTERS

Solana Beach, CA

MANUFACTURING

Irvine, CA

EUROPEAN HEADQUARTERS

London, UK

2022 EXPECTED REVENUE

\$21-22m

CASH & SHORT-TERM INVESTMENTS

\$45.1m^(A)

U.S. PATENTS ISSUED

75+^(B)

GROSS MARGIN

67%^(A,C)

EMPLOYEES

90+



(A) Estimated. Unaudited as of, and for the quarter ended, June 30, 2022

(B) Including owned and licensed patents

(C) For the Trailing Twelve Months (TTM)

Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance

PRIMARY CHALLENGE

For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head

MRI is the best imaging tool for the brain

Large, metallic frames are not MRI compatible





Big Iron companies like Siemens and Philips are innovating to make interoperative MRI scanners more accessible



Our Platform – Procedure Overview


The ClearPoint® Neuro Navigation System



Leverage live MR Imaging to Decide, Guide, Treat and Confirm with sub-millimetric accuracy.



Our Platform

SmartFrame® XG



SmartFrame XG Trajectory Tower
with ClearPoint 2.0 Software

SmartFrame Array™



SmartFrame Array Tower
with "virtual array" Software and next generation robotic
system with increased automation and enabling software*

ClearPoint plans to translate more than 10 years of experience
and over 5,000 cases performed in the complex MRI suite into
unique and competitive products for the Operating Room

Broad and Growing User Base of Leading Neurosurgery Centers

60+ Centers in the US, Canada and EU... and Growing Globally

UC San Francisco
Stanford University
Lucile Packard Children's Hospital
Benioff Children's Hospital
San Francisco VA
USC Keck Hospital
UC San Diego
Mayo Clinic in Arizona
University of Colorado
University of Utah
Cook Children's Hospital
Texas Children's Hospital
MD Anderson Cancer Center
Houston Methodist Hospital
Univ. Kansas Medical Center
Dallas Presbyterian Hospital
Cincinnati Jewish
Children's National
Banner Health Tucson
Ohio State University
University of Oklahoma Medical Center
Methodist Hospital San Antonio
Barnes-Jewish Hospital
Froedtert Hospital

University of Wisconsin
University of Michigan
University of Minnesota
Cleveland Clinic
Northwestern Central DuPage
Nationwide Children's
Le Bonheur
INOVA Fairfax
Cincinnati Children's Hospital

Charles River Labs – Laval
Charles River Labs – Mattawan
Children's Mercy Hospital
CHOA Scottish Rite
Carilion Clinic
UPMC
Hos. Univ. of Pennsylvania
Children's Hospital of Alabama
Emory University

Rigshospitalet (Copenhagen, Denmark)
Mazowiecki Szpital Bródnowski (Warsaw, Poland)
Hôpital Fondation Rothschild (Paris, France)
Skånes Universitetssjukhus Lund (Lund, Sweden)
University Hospital of Wales (United Kingdom)
Universitätsklinikum Düsseldorf (Düsseldorf, Germany)
Policlinico Umberto I (Rome, Italy)
Mt. Sinai West
Yale University
Weill Cornell
Johns Hopkins University
Boston Children's Hospital
Massachusetts General Hospital
Brigham & Women's
Duke University
National Institutes of Health
Memorial Sloan-Kettering
Dartmouth-Hitchcock
Beth Israel Deaconess
Children's Hospital of Philadelphia
Hackensack Univ. Med. Center
University of Virginia
Tampa General Hospital
Mayo Clinic in Florida

100+
Centers
Expected
by 2025

Our MRI-guided therapy platform is currently being used to...

CLPT PLATFORM RUNS ON ALL MAJOR SCANNERS

SIEMENS



PHILIPS

IMRIS

DELIVER BIOLOGICS AND DRUGS

PTC
THERAPEUTICS

BlueRock
Therapeutics

LYSOGENE

uniQure

charles river

IMPLANT NEURO STIMULATION LEADS

Medtronic

Abbott

Boston Scientific

NEUROPACE

PLACE LASER ABLATION PROBES

Medtronic
VISUALASE



MONTERIS
MEDICAL

CLEARPOINT
NEURO

*In partnership with
Clinical Laserthermia Systems AB.
510(k) pending

2013 - 2022

Growth in Case Volume and Revenue



ClearPoint Neuro Market Opportunity – United States

~\$12B+ Opportunity: Empowering Multiple Treatment Options for 35+ Indications*

**Pillar 4:
Global Expansion**
~2 X U.S. Revenue

Indication	Patient Population	Annual Incidence	Pillar 1: Drug/Cell Delivery	Pillar 2: DBS & BCI	Pillar 3: Laser Ablation	Incremental Revenue from Annual Incidence
Parkinson's Disease	1,000,000 ¹	60,000 ¹	○ ○	●	●	\$270 M - \$1.35 B
Drug Resistant Epilepsy	1,000,000 ²	11,000 ³	○ ○	●	●	\$49.5 M - \$198 M
Refractory Essential Tremor	3,500,000 ⁴	60,000 ⁵		●	○	\$180 M - \$1.08 B
Brain Tumors (n=3) ⁶	35,000 ^{7,8}	13,300 ^{7,8}	○ ○		●	\$33.3 M - \$300 M
Severe Obsessive-Compulsive Disorder	500,000 ^{9,10}	10,000 ^{9,10}		●		\$45 M - \$75 M
Dystonia	250,000 ¹¹	8,000 ¹²		●		\$36 M - \$60 M
Rare Genetic/Lysosomal (n=7) ¹³	36,500 ¹⁴⁻¹⁸	3,000 ^{14,19,20}	○ ○			\$13.5 M - \$67.5 M
Paralysis / Spinal Cord (n=15) ^{21,22}	331,000 ²²⁻²⁴	17,900 ²³	○ ○	○		\$80.6 M - \$403 M
Huntington's Disease	30,000 ²⁵	4,000 ²⁵	○ ○	○		\$18 M - \$90 M
Auditory Nerve Implant	1,867,000 ^{26,27}	7,000 ^{26,27}		○		\$31.5 M - \$63 M
Alzheimer's Disease	6,000,000 ²⁸	500,000 ²⁸	○ ○	○		\$1.5 B - \$11.3 B
Severe Major Depressive Disorder	1,000,000 ¹⁰	20,000 ^{10,29}		○		\$90 M - \$150 M
Stroke Rehabilitation	2,000,000 ³⁰	610,000 ³⁰		○		\$1.83 B - \$5.49 B
Frontotemporal Dementia	60,000 ³¹	12,000 ³¹	○			\$54 M - \$270 M
						\$4.2 B - \$20.8 B

ESTIMATED LAUNCH SEQUENCE

- Commercial U.S & EU ClearPoint procedures today
- Active clinical trial
- Pre-clinical study/testing



ClearPoint Neuro Navigation Capital, Robotics & Disposables
 Cannulas, Pumps | MER Probes | Laser Cath., Biopsy
 Access Technologies, Clinical Services, Digital Health

*Citations & footnotes on next slide




















ClearPoint Neuro Market Opportunity – United States

Citations & Footnotes

1. "Parkinson's Disease Statistics," Parkinson's News Today, <https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older>
2. Neuron Therapeutics. (2021 November 4). *Neuron Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients* [Press release] https://www.neurontherapeutics.com/wp-content/uploads/2021/11/2021_11_01_-INDClearance_FINALVersion.pdf
3. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. *World Neurosurg.* 2017;99:662-666.
4. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. *Neuropsychiatr Dis Treat.* 2010;6:401-408. Published 2010 Sep 7.
5. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. *Parkinsonism Relat Disord.* 2010;16(9):604-607.
6. Includes: Glioblastoma, Diffuse Intrinsic Pontine Glioma and deep small eloquent brain tumors.
7. "Glioblastoma Multiforme," American Association of Neurological Surgeons, <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme>
8. "About DIPG/DMG," DIPG/DMG Registry, <https://dipgregistry.org/patients-families/about-dipg-dmg/>
9. Medtronic Clinical Summary – Reclaim DBS for Chronic Extreme OCD M947128A001.
10. Mantovani A, Lisanby SH. Brain stimulation in the treatment of anxiety disorders. In: Simpson HB, Neria Y, Lewis-Fernández R, Schneier F, eds. *Anxiety Disorders: Theory, Research and Clinical Perspectives*. Cambridge: Cambridge University Press; 2010:323-335.
11. <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Dystonia>
12. Medtronic DBS™ Therapy for Dystonia - Clinical Summary 2015.
13. Includes: AADC deficiency, Friedreich's ataxia, Angelman syndrome, multiple system atrophy, metachromatic leukodystrophy, and spinocerebellar ataxia type 3.
14. "Multiple System Atrophy," Medscape, <https://emedicine.medscape.com/article/1154583-overview#a6>
15. PTC Therapeutics November 30, 2021 Corporate Presentation, <https://ir.ptcbio.com/static-files/0fd5d54f-55b8-416b-8006-4eb4c0d82f45>
16. "Spinocerebellar ataxia type 3," Orphanet, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757
17. Lysogene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020, http://www.lysogene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation_final.pdf
18. "Metachromatic Leukodystrophy," National Organization of Rare Disorders, <https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/>
19. "Aromatic L'Amino Acid Decarboxylase Deficiency," National Organization for Rare Disorders, <https://rarediseases.org/rare-diseases/aromatic-l-amino-acid-decarboxylase-deficiency/>
20. Puckett Y, Mallorga-Hernández A, Montañón AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. *Orphanet J Rare Dis.* 2021;16(1):241. Published 2021 May 29.
21. Includes: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, other (traumatic brain injury, complications from surgery, amyotrophic lateral sclerosis, neurofibromatosis, Chiari malformation, syringomyelia, postpolio syndrome, spinal muscular atrophy, Friedreich's ataxia, transverse myelitis, and spina bifida).
22. Armour BS, Courtney-Long EA, Fox MH, Fredine H, Cahill A. Prevalence and Causes of Paralysis-United States, 2013. *Am J Public Health.* 2016;106(10):1855-1857.
23. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. *Spinal Cord.* 2006;44(9):523-529.
24. National Spinal Cord Injury Statistical Center (NSCISC): 2020 Annual Report and 2021 Facts and Figures. <https://www.nscisc.uab.edu/>
25. "Huntington's Disease," *Mov Disord.* 2019 Jun; 34(6): 858–865.
26. "Cochlear Implants," National Institute on Deafness and Other Communication Disorders, <https://www.nidcd.nih.gov/health/cochlear-implants>
27. "Cochlear Implant Surgery," Medscape, <https://emedicine.medscape.com/article/857242-overview>
28. "Alzheimer's Disease: Facts & Figures," Brightfocus Foundation, <https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures>
29. Goodman WK, Alterman RL. Deep brain stimulation for intractable psychiatric disorders. *Annu Rev Med.* 2012;63:511-524.
30. "Stroke Facts," Center for Disease Control and Prevention, <https://www.cdc.gov/stroke/facts.htm>
31. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. *Int Rev Psychiatry.* 2013;25(2):130-137.

Innovation Pipeline

ClearPoint Neuro is Dedicated to Innovation in the Neuro Space

	Expected 2022 First-Use*	Expected First-Clinical Use by 2025*
Functional Navigation & Therapy	 <p>ClearPoint Neuro Navigation Software v. 2.1</p>  <p>ClearPoint Maestro™ Brain Model</p>  <p>Laser Ablation System*</p>	 <p>Brain Computer Interface Navigation</p>  <p>Maestro Sub-Nuclei Brain Model</p>  <p>Revolution™ Robotic-Assisted Navigation Closed Loop Robotic-Assisted Navigation</p>  <p>Micro-Electric Recording System (MER)</p>  <p>CT Based Navigation w/ Maestro Brain Model</p>  <p>MR Safe and "Smart" Biopsy Needles</p>
Biologics & Drug Delivery, Access Technologies	 <p>Expanded Pre-Clinical Development Services for Pharma</p>  <p>ClearPoint Maestro™ Infusion Modeling App</p>  <p>Pre-Clinical Head Fixation Frame</p>  <p>Operating Room Drill</p>	 <p>Orchestra Head Fixation Frame</p>  <p>ClearPoint Maestro™ Infusion Targeting App</p>  <p>Spinal Infusion Catheter</p>  <p>MRI Suite Safe Drill</p>  <p>Flexible, Chronic Drug Delivery Infusion Catheters</p>  <p>MyClearPoint™ Patient Digital Health App</p>

New Global Showcase Site

ClearPoint Global Training & Innovation Center – Solana Beach, CA

- Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback
- Showcase new technologies to Pharmaceutical and BCI partners
- Home for Clinical Specialists to support cases remotely without travel



4 Pillar Growth Strategy by 2025

Target Indications of > 1,000,000 Patients Diagnosed Each Year
Potential Total Addressable Market for CLPT of \$12B+



CLPT Capabilities Executive Summary



Unique platform technology
enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



Pipeline of new revenue streams
from product improvements, biologic and drug delivery partnerships and services, standalone therapy products, and Brain Computer Interface Navigation



Expandable Platform
with realizable synergies beyond the MRI and into the operating room and radiology suite



Large, growing installed base
in 60+ of 500+ leading Neurosurgery and research centers Worldwide



Total potential addressable market
> \$12B for our products, pipeline and partnerships



A growing and passionate team
of embedded scientists and specialists



© 2022 CLEARPOINT NEURO



CLEARPOINT[®]
NEURO



